Raut Nirmal V, Chordiya Nilesh
Department of Medical Oncology, Terna Sahyadri Hospital, Nerul, Navi Mumbai, India.
Indian J Med Paediatr Oncol. 2010 Jan;31(1):8-17. doi: 10.4103/0971-5851.68846.
Neoadjuvant chemotherapy (NACT) in breast cancer has undergone continuous evolution over the last few decades to establish its role in the combined modality management of these tumors. The process of evolution is still far from over. Many questions are still lurking in the minds of oncologists treating breast cancer. This review analyzes the evidence from metaanlyses, major multiinstitutional prospective trials, retrospective institutional series and systematic reviews in breast cancer to determine the current standards and controversies in NACT. The most effective drugs, their advantages, issues and controversies in delivery as well as the criteria for response are reviewed. A summary of evidence-based consensus is presented and unresolved aspects are discussed.
在过去几十年中，乳腺癌新辅助化疗（NACT）不断发展，以确立其在这些肿瘤综合治疗模式中的作用。然而，这一发展进程仍远未结束。许多问题仍萦绕在乳腺癌治疗肿瘤学家的脑海中。本综述分析了来自荟萃分析、大型多机构前瞻性试验、回顾性机构系列研究以及乳腺癌系统评价的证据，以确定NACT的当前标准和争议点。文中对最有效的药物、其优势、给药方面的问题和争议以及反应标准进行了综述。同时还给出了基于证据的共识总结，并讨论了尚未解决的方面。
